The efficacy and safety of thermal ablation for patients with lung malignancy: a meta-analysis of 12 studies in China

Table 2 Clinical outcomes of patients included in each study

Study	No. of patients	No. of ORR	No. of DCR	No. of CR	No. of PR	No. of SD	HR of OS	HR of PFS	No. of major complication
Hua Shen [9]							NA	NA
Group C	40	17	36	0	17	19			15
Group A + C	40	19	37	1	18	18			20
Sheng Li [10]							0.279	NA
Group C	22	NA	NA	NA	NA	NA			19
Group A + C	39	NA	NA	NA	NA	NA			26
Zhigang Wei [11]							0.59	0.33
Group C	28	NA	NA	NA	NA	NA			4
Group A + C	46	NA	NA	NA	NA	NA			5
Zilin Zhao [12]							NA	NA
Group C	49	32	34	NA	NA	NA			NA
Group A + C	47	38	41	NA	NA	NA			NA
Shuo Yu [13]							NA	NA
Group C	22	6	16	0	6	10			NA
Group A + C	35	28	33	0	28	5			NA
Wen-Hui Yang [14]							0.88	0.92
Group C	45	15	30	0	15	15			24
Group A + C	48	18	34	0	18	16			15
Chunhai Li [15]							NA	0.153
Group C	28	NA	NA	NA	NA	NA			19
Group A + C	21	NA	NA	NA	NA	NA			16
Zhigang Wei [16]							0.38	0.44
Group C	145	NA	NA	NA	NA	NA			93
Group A + C	148	NA	NA	NA	NA	NA			84
Ying-Qing Zhang [17]							NA	NA
Group C	42	4	26	0	4	22			NA
Group A + C	48	16	42	0	16	26			NA
Feng Xu [18]							0.47	0.5
Group C	128	57	87	19	38	30			NA
Group A + C	128	79	106	28	51	27			NA
Yuqing Shan [7]							NA	0.42
Group C	33	12	NA	0	12	NA			NA
Group A + C	34	24	NA	8	16	NA			NA
Kan Feng [19]							0.49	0.379
Group C	33	8	20	3	5	12			0
Group A + C	33	21	28	10	11	7			0

Group C group chemotherapy, Group A + C group ablation + chemotherapy, ORR objective response rate, DCR disease control rate, CR complete response, PR partial response, SD stable disease, HR hazard ratio, OS overall survival, PFS progression-free survival, NA not available

ISSN: 1749-8090